

CITATION REPORT

List of articles citing

Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure

DOI: 10.1038/hr.2016.193

Hypertension Research, 2017, 40, 535-540.

Source: <https://exaly.com/paper-pdf/65901339/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory. <i>Medical Hypotheses</i> , 2017 , 102, 61-64	3.8	1
30	Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 424-428	2.3	12
29	Clinical features and therapeutic perspectives on hypertension in diabetics. <i>Hypertension Research</i> , 2018 , 41, 213-229	4.7	11
28	Hypertension with diabetes mellitus complications. <i>Hypertension Research</i> , 2018 , 41, 147-156	4.7	43
27	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. <i>Heart Failure Reviews</i> , 2018 , 23, 419-437	5	53
26	Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 720-725	3.2	30
25	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. <i>Current Diabetes Reports</i> , 2018 , 18, 27	5.6	36
24	Circadian clock-mediated regulation of blood pressure. <i>Free Radical Biology and Medicine</i> , 2018 , 119, 108-114	7.8	91
23	Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1527-1535	2.3	28
22	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. <i>Frontiers in Endocrinology</i> , 2018 , 9, 421	5.7	53
21	Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	18
20	An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. <i>Hypertension Research</i> , 2018 , 41, 784-786	4.7	1
19	Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. <i>Chronic Diseases and Translational Medicine</i> , 2019 , 5, 25-36	3.9	3
18	SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. <i>Postgraduate Medicine</i> , 2019 , 131, 82-88	3.7	44
17	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
16	Valsartan-mediated chronotherapy in spontaneously hypertensive rats via targeting clock gene expression in vascular smooth muscle cells. <i>Archives of Physiology and Biochemistry</i> , 2019 , 1-11	2.2	1
15	Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus. <i>Hypertension Research</i> , 2019 , 42, 59-66	4.7	9

14	Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, F67-F75	4.3	13
13	Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
12	Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 7, 100058	1.6	
11	Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. <i>European Journal of Pharmacology</i> , 2020 , 875, 173040	5.3	38
10	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 249-262	8.5	21
9	Inverted circadian variation of arterial pressure in a geriatric patient: an indicator of autonomic dysfunction. <i>BMC Geriatrics</i> , 2021 , 21, 148	4.1	
8	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2021 , 1	5	2
7	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	10
6	Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
5	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. <i>Pharmacological Reviews</i> , 2022 , 74, 462-505	22.5	1
4	Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach. 2022 , 94,		0
3	Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. 9,		0
2	Possible renoprotective mechanisms of SGLT2 inhibitors. 10,		0
1	Timing Is Important Management of Metabolic Syndrome According to the Circadian Rhythm. 2023 , 11, 1171		0